CRINETICS PHARMACEUTICALS IN
CRNXNASDAQTrading Snapshot
- Day Range
- $84.05 – $85.41
- 52-Week Range
- $32.30 – $85.01
- Volume
- $2.32B
- Avg Volume
- $2.14B
- Shares Outstanding
- 105.8M
- Next Earnings
- Nov 27, 2026
Fundamentals Snapshot
- Annual Revenue
- $8M
- Last Q Revenue
- $25M
- P/E Ratio
- —
- P/S Ratio
- 213.8x
- EPS (TTM)
- $-5.05
- Dividend Yield
- —
- Dilution (1yr)
- +2.8%
Why Investors Own CRNX
- ✓High-growth profile — revenue up +48.2% YoY with expanding US Equity exposure.
- ✓Healthy economics — 36% gross margin and 13% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
CRINETICS PHARMACEUTICALS IN
CRNX
StockOtter · stockotter.spaceAbout CRINETICS PHARMACEUTICALS IN
Crinetics Pharmaceuticals, Inc. operates as a clinical-stage pharmaceutical enterprise, dedicated to the identification, advancement, and market introduction of therapeutic solutions for infrequent endocrine conditions and related tumors. Their flagship drug candidate, Paltusotine, is an orally administered, selective, non-peptide somatostatin receptor type 2 agonist. This compound has concluded its Phase III clinical trials for the treatment of acromegaly, and has also completed Phase II trials targeting carcinoid syndrome and nonfunctional neuroendocrine tumors (NETs). Furthermore, the company's pipeline includes CRN04777, an oral selective non-peptide somatostatin type 5 receptor agonist, which is currently undergoing Phase I clinical trials for congenital hyperinsulinism. Another investigational drug, CRN04894, an oral adrenocorticotrophic hormone antagonist, is in Phase I clinical trials for Cushing's disease and congenital adrenal hyperplasia. Crinetics Pharmaceuticals, Inc. was founded in 2008 and maintains its headquarters in San Diego, California.
Otter Score Breakdown
How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)Analyst Price Target
ⓘLatest News & Updates
CRINETICS PHARMACEUTICALS IN tops quarterly estimates as demand accelerates
Revenue grew double digits with management guiding above consensus; margins continued to expand.
Analysts lift CRNX price targets on improving margins
Several firms raised targets, citing stronger free cash flow and a healthier backlog.
CRINETICS PHARMACEUTICALS IN announces new agreement to expand its footprint
The move broadens the company’s reach and could add incremental revenue over the next year.